Sublicense Fees. Licensee will pay the following Non-Royalty Sublicense Fees on or before the Quarterly Payment Deadline for the Contract Quarter in which the applicable Non-Royalty Sublicensing Consideration is received by the Licensee:

Sublicense Fees. [Section 3.5] of the Penn-[[Organization A:Organization]] License is hereby deleted in its entirety.

Sublicense Fees. Licensee will pay Sublicense Fees indicated in [Section 3.1(d)] of the Agreement on or before the Quarterly Payment Deadline for the Contract Quarter.

Sublicense Fees. For the Medical Field of Use, for each sublicense granted by Licensee, Licensee shall pay to [[Organization A:Organization]] ten percent (10%) of that portion of any sublicense issue fees or license maintenance fees received by Licensee that are reasonably attributable to sublicenses of rights granted to Licensee hereunder. Funds received by Licensee from a sublicensee for research conducted by Licensee, achievement of product development-related performance milestones, or for equity investments in Licensee will not be subject to any fees hereunder.

In further consideration of the rights and licenses granted to Licensee under this Agreement, Licensee will pay Licensor ​ of any sublicense fees (​) received by Licensee or its Affiliates from a Third Party for the Licensed Technology from any Sublicensee or from any person or entity granted any option to obtain a sublicense (“Sublicensing Revenue”).

Sublicense Fees and Royalties. For each sublicense granted by Licensee, Licensee shall pay to [[Organization A:Organization]] fourteen percent (14%) of that portion of any sublicense issue fees or license maintenance fees received by Licensee which are reasonably attributable to sublicenses of rights granted to Licensee hereunder. Funds received by Licensee from a sublicensee for research conducted by Licensee, achievement of product development-related performance milestones, or for equity investments in Licensee will not be subject to any fees hereunder.

Sublicense Fees. For the Disinfectant Field of Use, for each sublicense granted by Licensee, Licensee shall pay to [[Organization A:Organization]] fourteen percent (14%) of that portion of any sublicense issue fees or license maintenance fees received by Licensee that are reasonably attributable to sublicenses of rights granted to Licensee hereunder. Funds received by Licensee from a sublicensee for research conducted by Licensee, achievement of product development- related performance milestones, or for equity investments in Licensee will not be subject to any fees hereunder.

Sublicense Fees. Licensee will pay Sublicense Fees indicated in Section 3.1(d) of the Patent License Agreement on or before the Quarterly Payment Deadline for the Contract Quarter.

Sublicense Fees. Licensee will pay the following Non-Royalty Sublicense Fees on or before the Quarterly Payment Deadline for the Contract Quarter in which the applicable Non-Royalty Sublicensing Consideration is received by the Licensee:

Sublicense Fees. As additional consideration for the license granted to [[AntriaBio:Organization]] under this Agreement, [[AntriaBio:Organization]] shall pay XOMA ​ of the Sublicense Fees received in connection with any sublicense under the license rights set forth in Section 3.1 granted prior to the earlier to occur of: # ​ paid to XOMA by [[AntriaBio:Organization]] ​; # ​; # ​. Subsequent to the occurrence of one of the foregoing events, [[AntriaBio:Organization]] shall pay XOMA ​ of the Sublicense Fees received in connection with any sublicense under the license rights set forth in Section 3.1 granted prior to the First Commercial Sale of a Licensed Product.